Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXOZYMES INC.EXOZ · Entity 1147 | Vice President- Finance | September 14, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXOZYMES INC.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.28 · Expires 2033-09-14 | Direct | 45,000 |
Reported balance
After 2026-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests over a three (3) year period in twelve (12) equal quarterly installments of 3,750 shares at the end of each quarter of the calendar year, commencing with the first full calendar quarter following the date of grant. The first installment vests on 12/31/2026 and the final installment vests on 09/30/2029. The option expires on 09/14/2033. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 9,488 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,488 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a three (3) year period in twelve (12) equal quarterly installments of 3,750 shares at the end of each quarter of the calendar year, commencing with the first full calendar quarter following the date of grant. The first installment vests on 12/31/2026 and the final installment vests on 09/30/2029. The option expires on 09/14/2033.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 21:27 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001493152-26-043174 · ownership.xml · derivative · entry 2 Nawaz Fouad · CIK 0002030838 · Vice President- Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-09-14 F1 · derivative.exercise_date: The option vests over a three (3) year period in twelve (12) equal quarterly installments of 3,750 shares at the end of each quarter of the calendar year, commencing with the first full calendar quarter following the date of grant. The first installment vests on 12/31/2026 and the final installment vests on 09/30/2029. The option expires on 09/14/2033. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 10:17 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCOMMON STOCK | 5,999 | $8.44 | $50,631.56 |
DisclosureSEC source: 0001493152-26-015622 · ownership.xml · nonDerivative · entry 1 Nawaz Fouad · CIK 0002030838 · Vice President- Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,488 Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:09 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCommon Stock | 3,489 | $12.54 | $43,752.06 |
DisclosureSEC source: 0001641172-25-015456 · ownership.xml · nonDerivative · entry 1 Nawaz Fouad · CIK 0002030838 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,489 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.